Lyell Immunopharma, Inc. (LYEL) insider buying and selling

NASDAQ: LYEL · Source: SEC Form 4 filings · Latest trade reported

In the last 90 days at Lyell Immunopharma, Inc. (LYEL), no insider made an open-market purchase and 4 insiders made 7 open-market sales worth $205K, as reported on SEC Form 4. All 7 sales were scheduled in advance or made to cover tax on vesting shares, so they say less about the insider's view of the stock. Over the last 12 months, 5 insiders sold $245K, of which $245K was scheduled or tax-related.

Insider buys, 90 days
0
$0 · 0 insiders
Insider sales, 90 days
7
$205K · 4 insiders
Insider buys, 12 months
0
$0 · 0 insiders
Insider sales, 12 months
12
$245K · 5 insiders

This is the public summary. Create a free account to see LYEL’s AI Signal, the price chart with every insider trade plotted, and each insider’s track record.

Unlock LYEL

Recent open-market insider trades

Trades by the same insider within a week are shown as one line.

No discretionary open-market insider trades were reported in the last 12 months.

Scheduled and tax-related sales

Sales made under a pre-arranged 10b5-1 plan or to cover tax on vesting shares. They are listed separately because they are not a fresh decision to sell.

Scheduled and tax-related insider sales at Lyell Immunopharma, Inc.
DateInsiderTypeSharesPriceValue
Lynn Seely
CEO
Sell to cover9,589$15.54$149K
Gary K. Lee
Chief Scientific Officer
Sell to cover1,457$15.54$23K
Stephen J. Hill
COO
Sell to cover989$15.54$15K
Veronica Sanchez Bulis
VP
Sell to cover621$14.34$9K
Lynn Seely
CEO
Sell to cover390$14.34$6K
Gary K. Lee
Chief Scientific Officer
Sell to cover131$14.34$2K
Stephen J. Hill
COO
Sell to cover89$14.34$1K
David Shook
Chief Medical Officer
Sell to cover1,977$12.64$25K

What the LYEL insider trades really mean

The table above is the public summary. With an Insider Intel account you get the analysis behind it, for Lyell Immunopharma, Inc. and every other stock we track:

The AI Signal weighs:Insider buyingAnalyst ratingPrice upsideAI OutlookInsider track recordBreakout pressure

Plus AI summaries, the latest news for each stock, and an AI assistant you can ask questions about any of it.

Get started free with LYEL Insider Intel tracks insider activity at 3,154 companies right now. The Free plan includes full price charts and trade history, watchlists and email alerts.

Questions about LYEL insider trading

Who bought Lyell Immunopharma, Inc. (LYEL) stock recently?

No insider made an open-market purchase of Lyell Immunopharma, Inc. (LYEL) stock in the last 12 months.

Are insiders buying or selling LYEL?

Insiders made no discretionary trades in LYEL over the last 12 months; the only sales were scheduled or tax-related.

What is a sell-to-cover or 10b5-1 sale?

A 10b5-1 sale is scheduled in advance under a pre-arranged plan, and a sell-to-cover sale is made to pay tax on vesting shares. Neither is a fresh decision to sell, so they say less about an insider's view than a discretionary sale.

Where does this data come from?

Officers, directors and large shareholders report their trades to the SEC on Form 4. This page lists the open-market purchases and sales by individual insiders from those public filings; funds and other institutions are not shown.

Other stocks with recent insider buying

Ready to see LYEL in full?

Create a free account and open its chart, score and alerts.

Create your free account

How to read this page

Officers, directors and large shareholders must report their trades in company shares to the SEC on Form 4. This page lists open-market purchases and sales by individual insiders: trades made on the stock exchange at the going price. Funds and other institutions are not shown here.

Information from SEC EDGAR Form 4 filings, shown for general information only. It is not financial advice and does not recommend buying or selling any security. Trades are shown by transaction date and may be reported up to two business days later.